Apricus Biosciences Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Apricus Biosciences

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mirror Image who wrote (1837)	4/11/2016 1:17:28 PM
From: mokelumne river	Read Replies (2) of 2026

Now that you have me reading the corporate presentation, it states on page 13: >Allergan retains the right to launch a future AG under a profit share structure with Apricus< What is "AG"? Is that shorthand for a separate "agreement"? Also, I get irritated with statements like this, also on page 13: >If Allergan elects to opt-in, Apricus may receive up to a total of $25 million in upfront and potential regulatory milestones, plus a double-digit royalty< We all know that the upfront could be as little as $1 million (or less) with the remaining $24 million in regulatory milestones payable who knows when. I did like the statement on page 14 that >no additional clinical studies (are) expected<. If they say that a few more times, even PR might become a believer.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next